A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC).

L Leon,S Maciá,J Casal,J V Cardona,J Gracia,J L Fírvida,S Vazquez,L Santomé,M Lázaro,M Amenedo

doi:10.1200/jco.2010.28.15_suppl.e18052

A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC).

L Leon, S Maciá + Show 8 more

https://doi.org/10.1200/jco.2010.28.15_suppl.e18052

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2010
Citations: 1

#Non-squamous Non-small Cell Lung Cancer #Squamous Non-squamous Non-small Cell Lung Cancer #anti-VEGF Monoclonal Antibody #Improves Response Rates #Chemotherapy-naive Patients #Lung Cancer #anti-VEGF Antibody #Galician Lung Cancer Group #Lung Cancer Group #Non-small Cell Lung Cancer

Abstract
Full-Text
Similar Papers

Abstract

Listen

e18052 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel and PFS when c...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC).